Acorn Capital Advisors, LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Acorn Capital Advisors, LLC reported 21 stock positions worth $295.1 million. Its top holding was Terns Pharmaceuticals (TERN) at 23.9% of the portfolio, followed by CG Oncology (CGON, 15.9%) and Urogen Pharma (URGN, 11.5%). Compared with Q3 2025, it opened 1 new position, added to 4 and reduced 3. The biggest buy was Cybin (HELP, shares +114%) and the biggest sale Q32 Bio (QTTB, shares −39%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002054410
- Portfolio Value
- $295.1M (Q4 2025)
- SEC Filing
- 0001636587-26-000005 ↗ filed Feb 17, 2026
Holdings Value
Holdings 21 stocks · $295.1M
| TERN Terns Pharmaceuticals Inc. | 23.90% | 1,746,264 | $70.5M | Reduce -11.4% |
| CGON CG Oncology Inc. | 15.92% | 1,131,501 | $47.0M | No change |
| URGN Urogen Pharma Ltd. | 11.49% | 1,448,420 | $33.9M | Add +15.0% |
| TRVI Trevi Therapeutics Inc. | 9.10% | 2,144,844 | $26.9M | No change |
| PBYI Puma Biotechnology Inc. | 8.33% | 4,131,299 | $24.6M | No change |
| CADL Candel Therapeutics Inc. | 4.94% | 2,580,517 | $14.6M | No change |
| HELP Cybin Inc. | 4.36% | 1,573,023 | $12.9M | Add +114.2% |
| VSTM Verastem Inc. | 3.84% | 1,469,153 | $11.3M | Add +88.5% |
| BCAX Bicara Therapeutics Inc. | 3.67% | 643,382 | $10.8M | No change |
| TARA Protara Therapeutic Inc. | 3.16% | 1,752,115 | $9.3M | No change |
| OKUR Onkure Therapeutics Inc. Class A | 2.79% | 2,839,674 | $8.2M | No change |
| CRDF Cardiff Oncology Inc. | 1.87% | 1,962,084 | $5.5M | No change |
| LONA Leonabio Inc. filed as ATHIRA PHARMA INC | 1.29% | 501,739 | $3.8M | New |
| JSPR Jasper Therapeutics Inc. | 1.11% | 1,786,492 | $3.3M | Add +29.2% |
| AURA Aura Biosciences Inc. | 1.10% | 595,744 | $3.2M | No change |
| WHWK Whitehawk Therapeutics Inc. | 0.93% | 1,139,363 | $2.8M | No change |
| BCAB Bioatla Inc. | 0.93% | 4,835,111 | $2.8M | No change |
| QTTB Q32 Bio Inc. | 0.56% | 493,425 | $1.6M | Reduce -38.6% |
| XFOR X4 Pharmaceuticals Inc. | 0.37% | 273,349 | $1.1M | No change |
| ACRV Acrivon Therapeutics Inc. | 0.33% | 405,237 | $977K | No change |
| VYNE THERAPEUTICS INC | 0.00% | 1,425 | $827 | Reduce -99.8% |
Portfolio Sells Q3 2025 → Q4 2025
| QTTB Q32 Bio Inc. | Reduce -38.6% | 0.56% | −0.25 |
| VYNE THERAPEUTICS INC | Reduce -99.8% | 0.00% | −0.10 |
| TERN Terns Pharmaceuticals Inc. | Reduce -11.4% | 23.90% | +16.39 |
Portfolio Buys Q3 2025 → Q4 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 20 | $366.5M | CGON, URGN, TRVI, CADL, PBYI |
| Q1 2026 | 22 | $351.8M | TERN, CGON, URGN, PBYI, TRVI |
| Q4 2025 | 21 | $295.1M | TERN, CGON, URGN, TRVI, PBYI |
| Q3 2025 | 20 | $197.0M | CGON, URGN, PBYI, TRVI, TERN |
| Q2 2025 | 21 | $152.9M | CGON, URGN, YMAB, PBYI, CADL |
| Q1 2025Amended | 22 | $149.9M | CGON, URGN, YMAB, TRVI, CADL |
| Q4 2024Amended | 21 | $185.8M | CGON, YMAB, CADL, URGN, PBYI |